Buy recommendation gilead sciences gild
1 / 16

BUY Recommendation: Gilead Sciences (GILD) - PowerPoint PPT Presentation

  • Uploaded on

BUY Recommendation: Gilead Sciences (GILD). Company Overview. Gilead Sciences, Inc. is a research-based biopharmaceutical company found in 1987 that discovers, develops and commercializes innovative medicines in areas of unmet medical need. . Current Portfolio. HIV vs Hepatitis. HIV Drug.

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about ' BUY Recommendation: Gilead Sciences (GILD)' - stew

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

Company overview
Company Overview

  • Gilead Sciences, Inc. is a research-based biopharmaceutical company found in 1987 that discovers, develops and commercializes innovative medicines in areas of unmet medical need. 

Hiv drug
HIV Drug

-Stribild (QUAD): First HIV treatment regimen that combine drugs from the same company.

-4 in one pill

-#1 HIV regimen in the US

Company profile
Company Profile

  • In 2012, Gilead was ranked #2 in Fortune magazine’s list of fastest-growing corporations by 10-year profits

  • In 2012, Harvard Business Review ranked Gilead’s Chairman and chief executive officer, John C. Martin, #5 on its list of the 100 best-performing CEOs in the world, as well as the top-ranked health care CEO.

Medicine patent pool mpp
Medicine Patent Pool (MPP)

Gilead is the first pharmaceutical company to sign an agreement with the Medicines Patent Pool, which is working to increase global access to high-quality, low-cost antiretroviral therapy through the sharing of patents. The Patent Pool has been granted similar licensing terms for Gilead HIV medicines as our generic manufacturing partners.

Gilead has Medicines Patent Pool the right to develop and distribute its in 100 developing countries.

Sofosbuvir vs competitors
Sofosbuvir vs Competitors

  • Gilead’s Sofosbuvir is all-oral treatment that has 100% cure rate through 2 stages of clinical trail.

  • Sofosbuvir is a once a day, single pill treatment that eliminates the need for interferon

Sofosbuvir vs competitors1
Sofosbuvir vs Competitors

  • Bristol Myers Squibb Co. (BMY) made its own big hep-C acquisition, but the experimental drug turned out to cause one patient death and complications with others, forcing the company to drop development.

  • Idenix Pharmaceuticals, Inc. (IDIX) had two of its hep-C prospects put on clinical holds back in November due to safety concerns. Idenix discontinued their clinical development programs for 2 hep-C drug candidates in February

Sofosbuvir vs competitors2
Sofosbuvir vs Competitors

  • Vertex Pharmaceuticals Incorporated (VRTX) and Merck & Co., Inc. (MRK) ’s Hep-C treatment require intravenous administration and can cause flu-like symptoms for nearly a year during treatment. Vertex’s Hep-C drug had 79% cure rate through 3 stages of clinical trail.

Sofosbuvir vs competitors3
Sofosbuvir vs Competitors

Striblid approved

Analyst Opinion: 20 Buy, 2 hold, 0 sell

GILD’s nearest nine competitors averaged 54% buys

Investment information
Investment Information

Striblid approved

GILD vs S&P Biotechnology Index

Portfolio placement recommendation
Portfolio Placement / Recommendation

  • Sector : Healthcare

  • Current Holdings: ABT, ABBV, HLF, XLV

  • Target Sector Allocation: 6%

  • Current Sector Allocation: ~4.9%

  • Remaining Allocation:~ 1.1%, ~$6000

  • BUY 125 shares of SGYP at market value (approx. $6000, 21% of portfolio)

  • Holding Period/Exit Strategy:  2-3 years. Aiming for long-term profitability and potential